Research progress in the mechanism of macrophages in atherosclerosis

doi:10.3877/cma.j.issn.2095-1221.2017.04.009

Abstract

Abstract:

Atherosclerosis (AS) is thought to be a chronic inflammatory response, in which macrophages play an important role. Macrophages can engulf inflammatory cells and fill the site of atherosclerotic lesions, which also can actively participate in cholesterol accumulation. They can also promote the formation of complex and unstable plaques. Meanwhile antiinflammatory macrophages contribute to tissue repair remodeling and plaque stabilization. Therefore, the mechanism of macrophage research may be a breakthrough in the treatment of atherosclerosis, so as to reduce the accumulation of mononuclear cells to the injured site, inhibit the activity of proinflammatory macrophages, promote cholesterol outflow, and reduce lipid storage. More in-depth studies are still needed to create a comprehensive classification of phenotypes for different macrophages and to determine their roles in the pathogenesis of atherosclerosis. In this paper, we discuss the diversity and activation of the macrophages in the process of atherosclerosis and provide a reference for the study of atherosclerosis based on macrophages.

Key words: Atherosclerosis, Macrophages, Inflammatory reactions, Liposomes

Wei Li, Li Zhu, Zhongbao Ruan, Yin Ren. Research progress in the mechanism of macrophages in atherosclerosis[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2017, 07(04): 237-241.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2017.04.009

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2017/V07/I04/237

References 44

[1]	Krauss RM. Lipoprotein subfractions and cardiovascular disease risk[J]. Curr Opin Lipidol, 2010, 21(4):305-311.
[2]	Tertov VV, Orekhov AN, Kacharava AG, et al. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis[J]. Exp Mol Pathol, 1990, 52(3):300-308.
[3]	Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance[J]. Nat Rev Immunol, 2013, 13(10):709-721.
[4]	Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis[J]. Nat Rev Immunol, 2014, 14(6):392-404.
[5]	Orekhov AN, Bobryshev YV, Chistiakov DA. The complexity of cell composition of the intima of large arteries: focus on pericyte-like cells[J]. Cardiovasc Res, 2014, 103(4):438-451.
[6]	Randolph GJ. Mechanisms that regulate macrophage burden in atherosclerosis[J]. Circ Res, 2014, 114(11):1757-1771.
[7]	Ziegler-Heitbrock L. The CD14⁺ CD16⁺ blood monocytes: their role in infection and inflammation[J]. J Leukoc Biol, 2007, 81(3):584-592.
[8]	Cros J, Cagnard N, Woollard K, et al. Human CD14 dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors[J]. Immunity, 2010, 33(3):375-386.
[9]	Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2007, 27(11):2292-2301.
[10]	Combadi E, Ley K. Vascular adhesion molecules bined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice[J]. Circulation, 2008, 117(13):1649-1657.
[11]	Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2009, 29(10):1424-1432.
[12]	Novoselov VV, Sazonova MA, Ivanova EA, et al. Study of the activated macrophage transcriptome[J]. Exp Mol Pathol, 2015, 99(3):575-580.
[13]	Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines[J]. Immunity, 2014, 41(1):14-20.
[14]	Chistiakov DA, Bobryshev YV, Nikiforov NG, et al. Macrophage phenotypic plasticity in atherosclerosis: The associated features and the peculiarities of the expression of inflammatory genes[J]. Int J Cardiol, 2015, 184(1):436-445.
[15]	Zizzo G, Hilliard BA, Monestier M, et al. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction[J]. J Immunol, 2012, 189(7):3508-3520.
[16]	Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization[J]. Front Biosci, 2008, 13:453-461.
[17]	Ferrante CJ, Pinhal-Enfield G, Elson G, et al. The adenosine-dependent angiogenic Switch of macrophages to an M2-like phenotype is Independent of interleukin-4 receptor alpha (IL-4Rα) signaling[J]. Inflammation, 2013, 36(4):921-931.
[18]	Gleissner CA, Shaked I, Little KM, et al. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages[J]. J Immunol, 2010, 184(9):4810-4818.
[19]	Gleissner CA. Macrophage phenotype modulation by CXCL4 in atherosclerosis[J]. Front Physiol, 2012, 3:1.
[20]	Cochain C, Zernecke A. Macrophages and immune cells in atherosclerosis: recent advances and novel concepts[J]. Basic Res Cardiol, 2015, 110(4):34.
[21]	Stchain C, Zernecke A. Macrophages and immune cells in atherosclerosis: recent advances and novel concepts[J]. Basic Res Cardiol, 2015, 110(4):34.
[22]	Chinetti-Gbaguidi G, Baron M, Bouhlel MA, et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways[J]. Circ Res, 2011, 108(8):985-995.
[23]	Orekhov AN, Sobenin IA, Gavrilin MA, et al. Macrophages in immunopathology of atherosclerosis: a target for diagnostics and therapy[J]. Curr Pharm Des, 2015, 21(9):1172-1179.
[24]	Boyle JJ, Harrington HA, Piper E, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype[J]. Am J Pathol, 2009, 174(3):1097-1108.
[25]	Boyle JJ, Johns M, Kampfer T, et al. Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated Iron handling and foam cell protection[J]. Circ Res, 2012, 110(1):20-33.
[26]	Orekhov AN, Nikiforov NG, Elizova NV, et al. Phenomenon of individual difference in human monocyte activation[J]. Exp Mol Pathol, 2015, 99(1):151-154.
[27]	Natoli G, Monticelli S. Macrophage activation: glancing into diversity[J]. Immunity, 2014, 40(2):175-177.
[28]	Ostuni R, Piccolo V, Barozzi I, et al. Latent enhancers activated by stimulation in differentiated cells[J]. Cell, 2013, 152(1/2):157-171.
[29]	Orekhov AN, Zhelankin AV, Kolmychkova KI, et al. Susceptibility of monocytes to activation correlates with atherogenic mitochondrial DNA mutations[J]. Exp Mol Pathol, 2015, 99(3):672-676.
[30]	Al-Sharea A, Lee MK, Moore XL, et al. Native LDL promotes differentiation of human monocytes to macrophages with an inflammatory phenotype[J]. Thromb Haemost, 2016, 115(4):762-772.
[31]	Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer[J]. Nat Immunol, 2010, 11(2):155-161.
[32]	Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive Oxygen species in response to minimally oxidized low-density lipoprotein[J]. Circ Res, 2009, 104(2):210-218.
[33]	Jiang Y, Wang M, Huang K, et al. Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive Oxygen species-dependent NLRP3 inflammasome activation[J]. Biochem Biophys Res Commun, 2012, 425(2):121-126.
[34]	Kadl A, Meher AK, Sharma PR, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2[J]. Circ Res, 2010, 107(6):737-746.
[35]	Huang Z, Li W, Wang R, et al. 7-ketocholesteryl-9-carboxynonanoate induced nuclear factor-kappa B activation in J774A.1 macrophages[J]. Life Sci, 2010, 87(19/22):651-657.
[36]	Huber J, Boechzelt H, Karten B, et al. Oxidized cholesteryl linoleates stimulate endothelial cells to bind monocytes via the extracellular signal-regulated kinase 1/2 pathway[J]. Arterioscler Thromb Vasc Biol, 2002, 22(4):581-586.
[37]	Yakubenko VP, Bhattacharjee A, Pluskota E, et al. αMβ₂ integrin activation prevents alternative activation of human and murine macrophages and impedes foam cell formation[J]. Circ Res, 2011, 108(5):544-554.
[38]	Boyanovsky BB, Li X, Shridas P, et al. Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines[J]. Cytokine, 2010, 50(1):50-57.
[39]	Dasu MR, Jialal I. Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors[J]. Am J Physiol Endocrinol Metab, 2011, 300(1):E145-E154.
[40]	Ishiyama J, Taguchi R, Yamamoto A, et al. Palmitic acid enhances lectin-like oxidized LDL receptor (LOX-1) expression and promotes uptake of oxidized LDL in macrophage cells[J]. Atherosclerosis, 2010, 209(1):118-124.
[41]	Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages[J]. J Biol Chem, 2002, 277(51):49982-49988.
[42]	Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity[J]. Circ Res, 2011, 108(2):235-248.
[43]	Ivanova EA, Bobryshev YV, Orekhov AN. LDL electronegativity index: a potential novel index for predicting cardiovascular disease[J]. Vasc Health Risk Manag, 2015, 11:525-532.
[44]	Kruth HS. Receptor-independent fluid-phase pinocytosis mechanisms for induction of foam cell formation with native low-density lipoprotein particles[J]. Curr Opin Lipidol, 2011, 22(5):386-393.

Please choose a citation manager

Content to export